Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs)), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others), By Sample (Tissue, Blood, Saliva and Buccal Swab, Others), By Method (DNA, RNA, Proteins), By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types), By Application (Clinical, Research), By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.73 Billion
CAGR (2026-2031)	15.28%
Fastest Growing Segment	Hospitals
Largest Market	North America
Market Size (2031)	USD 4.06 Billion

Market Overview

The Global Multicancer Screening Market is projected to grow from USD 1.73 Billion in 2025 to USD 4.06 Billion by 2031 at a 15.28% CAGR. Multicancer early detection (MCED) products are diagnostic tools that utilize liquid biopsy technology to identify biological signals, such as circulating tumor DNA, from multiple types of malignancies within a single blood sample. The primary drivers fueling market growth include the escalating global burden of oncological diseases and a systemic shift toward preventive healthcare models that prioritize non-invasive testing. Additionally, the unique capability of these assays to detect lethal cancers that currently lack standardized screening protocols provides a compelling value proposition for healthcare systems seeking to reduce late-stage diagnoses.

This urgent clinical demand is supported by the sheer volume of anticipated diagnoses. According to the American Cancer Society, in 2025, approximately 2,041,910 new cancer cases were projected to occur in the United States. Despite this clear necessity, the market faces a significant challenge regarding reimbursement mechanisms, as insurers often delay coverage decisions pending longitudinal data that demonstrates a definitive reduction in mortality rates.

Key Market Drivers

Advancements in Liquid Biopsy and Next-Generation Sequencing are fundamentally reshaping the Global Multicancer Screening Market by enabling the precise detection of circulating tumor DNA and methylation patterns associated with early-stage malignancies. These technological improvements allow for the simultaneous identification of signals from multiple cancer types through a single blood draw, significantly expanding diagnostic capabilities beyond traditional single-indication screenings. The clinical utility of these sophisticated platforms is increasingly supported by robust performance data, which is critical for adoption. For instance, according to GRAIL, October 2025, in the 'PATHFINDER 2 Study Update', adding the Galleri test to standard-of-care screenings resulted in a more than seven-fold increase in the number of cancers detected compared to standard screening alone. Such data underscores the efficacy of liquid biopsy in addressing the urgent need for tools that can identify lethal cancers lacking standardized screening protocols.

Strategic Collaborations and Partnerships in the Biotechnology Sector are further accelerating market growth as diagnostic companies align with technology and pharmaceutical leaders to secure funding and enhance commercial scalability. These alliances provide the necessary capital and operational support to navigate complex regulatory pathways and expand the distribution of multi-cancer early detection (MCED) tests. A notable example of this trend occurred when, according to GRAIL, November 2025, in the 'Third Quarter 2025 Financial Results', Samsung agreed to make an equity investment of $110 million in the company to support its continued development and commercialization efforts. The financial scale of the broader screening sector also highlights the resources available for these advancements; according to Exact Sciences, in 2025, the company generated revenue of $851 million for the third quarter, reflecting the strong commercial foundation upon which future multi-cancer solutions are being built.

Download Free Sample Report

Key Market Challenges

The rigid requirement for longitudinal mortality data to secure reimbursement constitutes a significant barrier to the commercial scalability of the Global Multicancer Screening Market. Because insurers generally delay coverage decisions until clinical utility is unequivocally proven, multicancer early detection (MCED) tests remain categorized as out-of-pocket expenses for most patients. This lack of payer support effectively limits the market to a niche segment of affluent individuals, preventing the widespread adoption necessary to drive revenue growth and achieve economies of scale. Without a pathway to standard insurance coverage, these diagnostic tools cannot transition from discretionary luxury items to essential components of population health management.

The detrimental impact of this financial barrier is amplified by existing difficulties in maintaining patient adherence to screening protocols. According to the Prevent Cancer Foundation, in 2025, only 51% of U.S. adults reported completing their routine cancer screenings, a figure that represents a notable decline from the previous year. This data highlights that patient engagement is already fragile even for established, frequently covered procedures. Consequently, the absence of reimbursement for new, expensive MCED assays will almost certainly result in negligible adoption rates among the broader population, directly stalling the market's trajectory.

Key Market Trends

The Integration of Artificial Intelligence and Deep Learning for Biomarker Discovery is revolutionizing the market by enhancing the sensitivity of assays for early-stage malignancies. Unlike traditional methods that rely on single-variant detection, these advanced algorithmic platforms analyze complex fragmentation patterns and methylation signatures to distinguish genuine tumor-derived signals from background somatic noise with high precision. This technological leap is critical for identifying cancers with low shedding rates, which often evade standard liquid biopsy techniques. For example, according to Harbinger Health, May 2025, in the 'Harbinger Health Showcases Multi-Cancer Early Detection Performance' press release, their AI-enabled platform demonstrated a 25.8% sensitivity for early-stage cancers at 98.3% specificity within a high-risk population, validating the capability of machine learning to improve detection accuracy.

The Integration of Multicancer Screening into Corporate Wellness Programs represents a pivotal commercial shift designed to bypass current reimbursement hurdles. Diagnostic developers are increasingly bypassing traditional payer channels by partnering directly with self-insured employers and life insurance providers, positioning MCED tests as premium health benefits for employee retention and preventive care. This B2B strategy secures immediate revenue streams and generates real-world evidence while insurance coverage policies remain in development. The financial impact of this adoption channel is evident; according to GRAIL, November 2025, in the 'Third Quarter 2025 Financial Results', the company reported that Galleri revenue grew 29% year-over-year to $32.8 million, driven largely by expanded commercial partnerships and employer adoption.

Segmental Insights

The Hospitals segment is projected to be the fastest-growing end-use category in the Global Multicancer Screening Market. This expansion is driven by the pivotal role hospitals play in the "diagnostic resolution" phase; unlike standalone clinics, they possess the advanced imaging and surgical infrastructure required to confirm the tissue of origin following a positive multi-cancer early detection (MCED) result. Furthermore, substantial clinical validation programs, such as those overseen by the National Health Service (NHS) in the United Kingdom, rely heavily on hospital networks to coordinate these complex care pathways, thereby accelerating the adoption of screening protocols within these institutions.

Regional Insights

North America maintains a dominant position in the global multicancer screening market due to favorable regulatory frameworks and substantial healthcare investment. The region benefits from the active involvement of the US Food and Drug Administration, which facilitates the review and authorization of new early detection technologies. Furthermore, the high concentration of established industry players drives continuous product development and commercialization. Strong government initiatives supporting cancer prevention also encourage higher adoption rates. This established medical infrastructure and policy support secure North America’s status as the primary market for multicancer screening solutions.

Recent Developments

• In June 2025, GRAIL announced positive top-line results from its registrational PATHFINDER 2 study, which evaluated the safety and performance of the Galleri multi-cancer early detection (MCED) test. The study, involving over 35,000 participants, demonstrated that adding the Galleri test to standard-of-care screenings substantially increased the number of cancers detected compared to standard screening alone. The results showed a significant improvement in the positive predictive value and maintained high specificity. The President of GRAIL stated that the findings reinforced the potential of the MCED test to transform population-scale cancer screening by identifying cancers that currently lack recommended screening tests.
• In March 2025, Exact Sciences commenced the commercial rollout of Cologuard Plus, its next-generation multi-target stool DNA test, following FDA approval and the securing of Medicare coverage. The launch introduced an improved version of the company's flagship screening product, featuring novel biomarkers that enhanced specificity and reduced false-positive rates by approximately 30% compared to the original test. This product launch was part of the company's broader strategy to eradicate cancer through earlier detection and improved screening adherence. The company also raised its full-year financial outlook, reflecting confidence in the commercial adoption of the new test.
• In November 2024, Mainz Biomed announced a strategic collaboration with Thermo Fisher Scientific to jointly develop and potentially commercialize a next-generation colorectal cancer screening product. The agreement aimed to leverage Thermo Fisher's advanced technologies and instrumentation to enhance the development of Mainz Biomed's proprietary mRNA-based assays, which are designed to detect precancerous lesions such as advanced adenomas. The partnership focused on combining the companies' capabilities to accelerate the availability of an innovative, home-collection screening tool globally. The Chief Executive Officer of Mainz Biomed highlighted that the collaboration would be instrumental in bringing highly effective detection solutions to the market.
• In July 2024, Guardant Health achieved a significant regulatory milestone with the FDA approval of its Shield blood test for colorectal cancer screening in adults aged 45 and older who are at average risk. This approval marked the first time a blood test was authorized as a primary screening option for this indication, allowing healthcare providers to offer a non-invasive alternative to traditional methods like colonoscopy. The approval was supported by results from the ECLIPSE study, which demonstrated 83% sensitivity for detecting colorectal cancer. This development represented a major step forward in the company's efforts to expand access to early cancer detection using its liquid biopsy platform.

Key Market Players

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Konica Minolta, Inc.

By Test Type	By Technology	By Sample	By Method	By Cancer Type	By Application	By End User	By Region
Laboratory Developed Tests (LDTs) In-Vitro Diagnostics (IVDs)	Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Immunohistochemistry (IHC) Fluorescence In-Situ Hybridization (FISH) Others	Tissue Blood Saliva and Buccal Swab Others	DNA RNA Proteins	Breast and Gynecologic Gastrointestinal Endocrine Genitourinary Skin Brain/Nervous System Sarcoma Hematological Malignancies Lung Head and Neck Other Cancer Types	Clinical Research	Hospitals Diagnostic and Clinical Laboratories Academic Research Institutions Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Multicancer Screening Market, By Test Type:

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

• Multicancer Screening Market, By Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence In-Situ Hybridization (FISH)
• Others

• Multicancer Screening Market, By Sample:

• Tissue
• Blood
• Saliva and Buccal Swab
• Others

• Multicancer Screening Market, By Method:

• DNA
• RNA
• Proteins

• Multicancer Screening Market, By Cancer Type:

• Breast and Gynecologic
• Gastrointestinal
• Endocrine
• Genitourinary
• Skin
• Brain/Nervous System
• Sarcoma
• Hematological Malignancies
• Lung
• Head and Neck
• Other Cancer Types

• Multicancer Screening Market, By Application:

• Clinical
• Research

• Multicancer Screening Market, By End User:

• Hospitals
• Diagnostic and Clinical Laboratories
• Academic Research Institutions
• Others

• Multicancer Screening Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE